<DOC>
	<DOCNO>NCT03069326</DOCNO>
	<brief_summary>The purpose study test good bad effect study drug call ruxolitinib thalidomide . Ruxolitinib thalidomide could shrink cancer , could also cause side effect .</brief_summary>
	<brief_title>A Clinical Study Test Effects Ruxolitinib And Thalidomide Combination Patients With Myelofibrosis</brief_title>
	<detailed_description />
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Diagnosis myelofibrosis ( either primary post essential thrombocythemia/polycythemia vera ) require therapy , include previously treat relapsed refractory , newly diagnose , intermediate1 2 high risk accord International Working Group ( IWG ) criterion . Patients take ruxolitinib time enrollment must take ruxolitinib minimum 3 month , must stable dose ruxolitinib minimum 4 week immediately prior enrollment . Patients take ruxolitinib time enrollment must deem suboptimal response ( less partial response per IWG criterion ) ruxolitinib singleagent therapy deem progression disease ( per IWG criterion ) . Age ≥ 18 year time signing informed consent . ECOG performance status 0 2 . Patients must adequate organ function demonstrate follow : 1 . Direct bilirubin &lt; 2.0 mg/dL , unless due Gilbert 's disease 2 . Serum creatinine &lt; 2.0 mg/dL . 3 . ALT AST ≤ 3 x upper limit normal ( unless transaminitis consider related MF Females childbearing potential ( FCBP ) † must negative serum urine pregnancy test sensitivity least 50 mIU/mL within 14 day prior within 24 hours* start thalidomide must either commit continued abstinence heterosexual intercourse begin TWO acceptable method birth control , one highly effective method one additional effective method AT THE SAME TIME , least 4 week start take thalidomide . FCBP must also agree ongoing pregnancy test . Men must agree use condom sexual contact female child bear potential even successful vasectomy . All patient must counsel minimum every 28 day pregnancy precaution risk fetal exposure . All study participant must register mandatory REMS® program , willing able comply requirement REMS® Platelets ≥ 50000/uL ANC ≥ 1000 All study participant must able swallow oral medication Use standard antineoplastic drug growth factor ( e.g. , anagrelide , GCSF , revlimid , clofarabine ) except hydroxyurea experimental drug , exception Ruxolitinib , less 14 day 5half life prior start study therapy and/or lack recovery toxicity previous therapy grade 1 well . Known prior clinically relevant hypersensitivity reaction thalidomide , include development erythema nodosum characterize desquamate rash . Prior therapy thalidomide combination ruxolitinib Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form , place subject unacceptable risk he/she participate study confounds ability interpret data study . Lactating female . Known positive HIV hepatitis B C per institutional standard care Participants prior history thromboembolic disease ( i.e . deep venous thrombosis ( DVT ) pulmonary embolism ( PE ) within last six month , thalidomide demonstrate increase risk DVT PE Known hypercoagulability syndrome ( e.g . : antithrombin III , deficiency , anticardiolipin syndrome etc ) . Concurrent use strong inducer strong inhibitor CYP3A4 ( strong inducer rifampin St. John 's Wort , carbamazepine , phenytoin , barbiturates phenobarbital ; strong inhibitor HIVantivirals , clarithromycin , itraconazole , ketoconazole , nefadozone telithromycin ) . Concurrent use strong inducer strong inhibitor CYP3A4 ( strong inducer rifampin St. John 's Wort , carbamazepine , phenytoin , barbiturates phenobarbital ; strong inhibitor HIVantivirals , clarithromycin , itraconazole , ketoconazole , nefadozone telithromycin ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ruxolitinib</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>16-1498</keyword>
</DOC>